We are currently negotiating a development and license agreement under which a large pharmaceutical company (big pharma) will pay for the ongoing research and development (R&D) costs of our project. In this context, we urgently need professional guidance on the accounting treatment of this funding: should it be recognized as our revenue, followed by recognition of our R&D expenses? Or should it be treated as reimbursement of expenses we have already incurred? Or is there another more appropriate treatment?

The core of this issue lies in the specific structure of the contract terms, especially factors such as the nature of the payment, risk allocation, and intellectual property ownership. Generally, the accounting treatment requires judgment based on relevant accounting standards (such as IFRS 15 or ASC 606), with a focus on assessing whether the arrangement constitutes a customer contract and whether the payment is linked to specific performance obligations.

Key Judgment Factors

When determining the accounting treatment, it is recommended to analyze the following dimensions:

  • Nature of the Payment:Is the payment compensation for costs already incurred (i.e., reimbursement), or is it prepaid consideration for obtaining future R&D services?
  • Risk and Rewards:Does your company still bear the primary risk of R&D failure? If the pharmaceutical company bears all costs and no refund is required, it may be closer to revenue recognition.
  • Intellectual Property Ownership:Who owns the intellectual property of the R&D results? If it belongs to the pharmaceutical company, it may constitute revenue from R&D services; if it belongs to your company, it may be viewed as funding or a collaboration arrangement for your R&D activities.
  • Contractual Obligations:Does your company have an obligation to deliver specific results or provide ongoing services in the future? If so, revenue should be recognized based on the progress of performance.

Common Treatment Models

Based on practical experience, there are typically three treatment models:

  1. Revenue Recognition Model:If the payment is consideration from the pharmaceutical company for R&D services, and your company retains control over the R&D activities, revenue should be recognized as performance obligations are satisfied (usually over time or at milestones), while R&D costs incurred are expensed in the period.
  2. Expense Reimbursement Model:If the payment is strictly limited to compensating your company for actual, clearly attributable R&D expenses incurred, and does not generate a profit, it may be treated as expense reimbursement, i.e., offsetting R&D expenses upon receipt without recognizing revenue.
  3. Collaboration Arrangement Model:If both parties jointly participate in R&D and share risks, it may constitute a collaboration arrangement, requiring accounting on a net or gross basis depending on whether your company is the principal.

Important Note: Due to the lack of specific contract terms, the above analysis is only general guidance. It is strongly recommended that your company consult professional accountants or auditors to make a specific judgment based on the full contract and applicable accounting standards.

Additionally, consideration should be given to whether the arrangement involves accounting for a license. If the agreement includes an intellectual property license, it is necessary to assess whether the license constitutes a separate performance obligation and allocate the transaction price accordingly. If the payment from the pharmaceutical company includes a license fee, revenue may need to be recognized when control of the license transfers, rather than progressively as R&D costs are incurred.

Finally, it is recommended to work closely with the finance team during the contract negotiation stage to ensure that contract terms are clear and unambiguous, so that subsequent accounting treatment has a solid basis. If contract terms are unclear, disputes may arise over the timing or amount of revenue recognition, thereby affecting the accuracy of financial statements.